Regen BioPharma Inc. maintains its La Mesa research headquarters in a 2,320-square-foot suite on Spring Street near the Village district, operating as a publicly traded biotechnology company under OTC ticker symbols RGBP and RGBPP since its 2012 incorporation. The company's lead therapeutic asset HemaXellerate holds FDA Investigational New Drug clearance for treating aplastic anemia using adipose-derived cellular therapy, positioning the firm within a Grossmont-area medical corridor that includes cardiovascular and hematology specialists like Payam Mehranpour, MD - La Mesa Cardiac Center. DiffronC, a second pipeline candidate, addresses molecular differentiation blockades in oncology applications, while dCellVax deploys gene-silencing mechanisms to modulate immune checkpoint pathways. The 91942 ZIP code office functions as the corporate and regulatory hub for SEC filings, patent administration, and clinical trial coordination rather than as a retail dispensing location. Pre-clinical research partnerships extend into the gastroenterology and immunology networks surrounding Sharp Grossmont Hospital, overlapping with the referral base of San Diego Advanced Gastroenterology Associates on the Fletcher Parkway corridor. Highest-tier development efforts include the pending Orphan Drug Designation application for HemaXellerate's aplastic anemia indication and ADAS (Autologous Donor Adipose Stem) cell processing protocols designed to meet FDA 21 CFR Part 1271 human cells, tissues, and cellular product regulations.